文献速递头颈部肿瘤放疗姑息放疗与转移瘤

头颈部鳞状细胞癌姑息治疗的适宜放疗剂量(OpRAH):一项3期随机对照试验

Optimum radiation dose for palliation in head and neck squamous cell carcinoma (OpRAH) - A phase 3 randomized controlled trial.
PubMed 文献 · Radiother Oncol · 2024-11-08

该3期随机对照试验纳入305例不适合根治性治疗的非转移性局部晚期头颈部鳞状细胞癌患者,随机分为A组(20 Gy/5次/5天)和B组(30 Gy/5次/5天)。中位随访13.9个月时,两组无进展生存期(P=0.553)和总生存期(P=0.203)均无显著差异,毒性相似,剂量递增未带来进一步获益。

要点

  • A组20 Gy/5次/5天与B组30 Gy/5次/5天相比,PFS(P=0.553)和OS(P=0.203)无显著差异。
  • 两组毒性发生率相似,剂量递增耐受性良好。
  • 体能状态较好的患者总生存期显著更优。

核心结论

  • 这是分析每周姑息放疗方案安全性和有效性的最大3期随机对照试验,未证明剂量递增带来进一步改善。

研究设计与样本

  • 3期随机对照试验,纳入非转移性局部晚期头颈部鳞状细胞癌患者(n=305)随机分为A组(20 Gy/5次/5天)和B组(30 Gy/5次/5天)。
  • 2020年4月至2023年8月共随机390例患者,其中305例符合最终分析条件。

主要发现

  • 中位随访13.9个月时,整个队列的无进展生存期(PFS)为7.4个月,中位总生存期(OS)为10.03个月。
  • 两组PFS(P=0.553)和OS(P=0.203)无显著差异。
  • 两组毒性发生率相似,剂量递增耐受性良好。
  • 体能状态较好的患者总生存期显著更优。
  • 接受新辅助化疗、接受根治性转化或进展后接受姑息性化疗的患者中,未观察到OS或PFS的显著获益。

关键数值与推荐

  • A组放疗方案为20 Gy/5次/5天,B组为30 Gy/5次/5天。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiotherapy is frequently employed for palliative treatment in locally advanced head and neck squamous cell carcinoma (HNSCC) but radiation dose fractionation regimens are not well-defined. We designed this phase 3 randomized controlled trial to compare two weekly hypo fractionated regimes and study the effect on progression-free survival (PFS) in this subset of patients. MATERIALS AND METHODS: Non-metastatic locally advanced HNSCC patients (n = 305) who were not suitable for curative treatment were randomized to Arm A (20 Gy/5#/5 days) and Arm B (30 Gy/5#/5 days). PFS and OS were recorded along with acute toxicity using patient-reported quality of life HN QLQ 43. RESULTS: From April 2020 to August 2023, 390 patients were randomized, of which 305 were eligible for final analysis. At a median follow-up of 13.9 months, PFS and median overall survival (OS) for the entire cohort was 7.4 and 10.03 months, respectively. PFS (p-0.553) and OS (p-0.203) did not differ significantly between the two groups. Toxicity rates were similar between the two arms and dose escalation was well tolerated. Patients with a better PS were found to have significantly better OS. No significant benefit in OS or PFS was observed in patients who received neoadjuvant chemotherapy (NACT), underwent definitive conversion, or received palliative chemotherapy at progression. CONCLUSION: This is the largest phase 3 RCT to analyze the safety and efficacy of weekly palliative radiotherapy regimens and has not demonstrated further improvement with dose escalation.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Mallick S, Dagar A, Ghosh A, et al. Optimum radiation dose for palliation in head and neck squamous cell carcinoma (OpRAH) - A phase 3 randomized controlled trial. Radiother Oncol. 2024. PMID: 39522825. doi:10.1016/j.radonc.2024.110611

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。